Contract analysis

I. Executive Summary This quarterly report covers what has become the most significant period of the IRS's transfer pricing examination of Penterra Pharmaceuticals Corp. ("PPC") to date. Most critically, the Internal Revenue Service issued its Notice of Proposed Adjustment ("NOPA") on October 12, 2023. Although the NOPA was formally issued just outside the Q3 reporting period, we address it substantively in this repo

II. Examination Status and Q3 Activity A. IDR Completion The Information Document Request phase of the examination is now complete. Over the course of the examination, a total of forty-seven (47) IDRs were issued by the IRS examination team between June 2022 and September 2023. During Q3 2023, C&H prepared and submitted responses to IDRs Nos. 40 through 47, the final tranche of information requests. The responses wer

III. Notice of Proposed Adjustment (NOPA) — October 12, 2023 A. Issuance and Overview As noted in the Executive Summary, although the NOPA was formally issued on October 12, 2023—technically falling outside the Q3 2023 reporting period—it is addressed substantively in this report given its critical importance to the engagement and the fact that the NOPA was anticipated and substantially prepared for during Q3 2023. T

1. CSA Cost-Sharing Ratio Adjustments ($235.01 Million) The IRS proposes increasing PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points across each tax year. The IRS asserts that PPC's projections of reasonably anticipated benefits systematically understated U.S.-source value, resulting in PBI bearing an insufficient share of the intangible development costs incurred under the arrangement. The pr

2. Legacy IP Royalty Rate Adjustments ($188.04 Million) The IRS proposes increasing the royalty rate payable by PBI to PPC for the use of pre-existing intellectual property from PPC's reported rate of 4.5% of net sales to 11.0% of net sales. The IRS bases this adjustment on CUT data drawn from third-party pharmaceutical licensing agreements that Dr. Washburne identified as comparable to the PPC-PBI arrangement. The p

3. Economic Substance Challenge In addition to the pricing-based adjustments described above, the IRS asserts that PBI lacked sufficient economic substance to justify its role as intellectual property owner and CSA participant. The IRS's position is that key DEMPE functions remained in the United States under PPC's direction and control, and that PBI served primarily as a conduit entity without the personnel, infrast

4. Correlative Offset and Net Adjustment The IRS allowed a correlative offset of $42.65 million to avoid double-counting between the CSA cost-sharing ratio adjustments and the legacy IP royalty rate adjustments, where both adjustments would otherwise produce overlapping income allocations for the same underlying transactions. The net proposed adjustment is calculated as follows: CSA Cost-Sharing Ratio Adjustments: $2

5. Proposed Penalty The NOPA includes a proposed penalty under IRC § 6662(e) for substantial valuation misstatement. The penalty is calculated at 20% of the underpayment of tax attributable to the proposed adjustments: Proposed adjustment: $380.4M Federal income tax at 21%: $79.88M Penalty at 20% of underpayment: $15.98M (approximately) The IRS reserved but did not assert the 40% gross valuation misstatement penalty

IV. Upcoming Procedural Steps A. 30-Day Letter A 30-Day Letter from the IRS is anticipated imminently following the issuance of the NOPA. (We note that the 30-Day Letter was in fact issued on November 8, 2023, shortly after the date of this report, consistent with our expectations.) The 30-Day Letter will formally transmit the examination results to PPC and will provide PPC with the following options: (a) Accept the

V. Coordination with Third Parties A. Whitmore Valuation Group LLC Whitmore Valuation Group LLC ("WVG"), led by Dr. Helena Vasquez (Managing Director) and Dr. Rohan Chakrabarti (Senior Director), continues to provide critical economic analysis support in connection with the transfer pricing examination defense. WVG's engagement is structured under a Kovel arrangement (reference: Matter 1018-00009-KV, executed June 20

VI. PBI Substance Evidence — Summary Update The economic substance of PBI is a central issue in the IRS's proposed adjustments and will be a key focus of the Protest and Appeals proceedings. C&H's functional analysis of PBI, originally prepared in October 2022 and updated in March 2023, comprehensively documents PBI's operations, personnel, governance, and decision-making authority. The following is a summary of the

VII. Financial and Disclosure Considerations A. FIN 48 / ASC 740-10 Reserve PPC's current FIN 48 reserve for uncertain tax positions related to the Irish intellectual property structure stands at $62.4 million (pre-settlement basis). This reserve was established based on PPC's assessment of the probability and magnitude of potential adjustments to its transfer pricing positions, taking into account the strength of PP

VIII. Statute of Limitations C&H continues to monitor the statute of limitations for all four tax years under examination. The current status of the assessment period for each tax year is as follows: The issuance of the NOPA preserves the IRS's position on all four tax years, but the consent extensions for TY 2017 and TY 2018 must remain in effect through final resolution of the matter—whether through agreement at Ap

IX. C&H Engagement Team and Staffing There were no changes to the C&H engagement team during Q3 2023. The current team is as follows: C&H anticipates a significant increase in team activity during Q4 2023 and Q1 2024 as the engagement transitions from the examination phase to the Protest preparation and Appeals phase. The Protest will require substantial drafting and coordination with WVG and Crestfield, and the Appe

X. Budget and Fee Summary A. C&H Fees Through Q3 2023 C&H's fees billed through September 30, 2023 total approximately $3.8 million. This figure remains within the lower half of the original estimated fee range of $4.5 million to $7.0 million communicated to PPC at the commencement of the engagement. The Protest preparation, Appeals strategy development, and Appeals conference will constitute the bulk of the remainin

XI. Next Steps and Action Items The following action items have been identified for the coming quarter and will be executed as described:

1. NOPA Analysis. C&H (Simmons and Nazari) to complete a detailed analysis of the NOPA, including a line-by-line review of the proposed adjustments, the supporting economic report, and the legal memorandum. Target completion: October 20, 2023.

2. Client Communication. Cross to schedule a conference call with Whitfield, Staines, and Iyer to discuss the NOPA and C&H's recommended response strategy. The call should be scheduled promptly following completion of the NOPA analysis. 3. 30-Day Letter Response. Upon receipt of the 30-Day Letter, C&H will review the letter and, if necessary, request an extension of time to file the formal Protest.

4. Formal Protest Preparation. C&H to begin drafting the formal Protest immediately. Target filing: within thirty (30) days of the date of the 30-Day Letter, with extension if needed to finalize the WVG rebuttal memorandum and compile supporting exhibits.

5. Whitmore Rebuttal Memorandum. Dr. Vasquez and Dr. Chakrabarti at WVG to prepare a comprehensive rebuttal memorandum addressing Dr. Washburne's economic analysis, including CUT comparability, WACC determination, RAB methodology, and PCT revaluation. The rebuttal memorandum is to be prepared on an expedited basis for inclusion with the Protest.

6. FIN 48 / ASC 740-10 Update. C&H to prepare an updated FIN 48 analysis and letter to Crestfield & Associates providing updated legal conclusions regarding uncertain tax positions for use in PPC's year-end 2023 financial statement audit.

7. SEC Disclosure Analysis. C&H to prepare a memorandum analyzing PPC's disclosure obligations under SEC rules and ASC 450/ASC 740-10 in connection with the NOPA, for use in PPC's upcoming 10-K filing.

8. Hargrove Credit Facility Covenant Review. C&H (Nazari) to analyze the terms of the $1.5 billion revolving credit facility with Hargrove National Bank, N.A. to determine whether the proposed adjustments trigger any notice, reporting, or default provisions under the credit agreement.

9. Appeals Strategy Development. Following the Protest filing, C&H to prepare a comprehensive Appeals strategy memorandum, a hazards-of-litigation analysis, and a settlement authority recommendation for PPC management review and approval.

10. Statute of Limitations Monitoring. C&H to continue monitoring the statute of limitations for all four tax years. No additional Form 872 extension requests are anticipated at this time, given the goal of resolving the matter at Appeals before December 31, 2024.

XII. Conclusion The issuance of the NOPA on October 12, 2023 marks a significant milestone in the IRS's transfer pricing examination of PPC's intercompany transactions with PBI for Tax Years 2017 through 2020. While the proposed $380.4 million adjustment and $15.98 million penalty represent a substantial assertion by the IRS—and one that carries a total potential cash exposure of approximately $95.86 million before i